UroGen Pharma Ltd. Announces Executive and Board Changes

Ticker: URGN · Form: 8-K · Filed: 2025-08-27T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-composition, executive-compensation

Related Tickers: URGN

TL;DR

UroGen Pharma reshuffled execs and board members on 8/26. New directors elected, comp plans updated.

AI Summary

UroGen Pharma Ltd. announced on August 26, 2025, several key executive and board changes. The company elected new directors and appointed new officers, alongside updates to compensatory arrangements for certain executives. These changes are effective as of August 26, 2025.

Why It Matters

Changes in executive leadership and board composition can signal shifts in company strategy, operational focus, or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

FAQ

Who were the specific individuals appointed or departing from UroGen Pharma Ltd.'s board or executive team?

The filing indicates the election of directors and appointment of officers but does not name the specific individuals involved in these changes.

What were the specific compensatory arrangements updated for certain officers?

The filing mentions updates to compensatory arrangements for certain officers but does not provide details on the nature or terms of these arrangements.

Were there any shareholder votes or proposals discussed in this 8-K filing?

The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item information, suggesting such matters were addressed, but details are not provided in this excerpt.

What financial statements or exhibits were filed alongside this 8-K?

The filing lists 'Financial Statements and Exhibits' as an item information, but the specific content of these exhibits is not detailed in this excerpt.

What is the primary business of UroGen Pharma Ltd. according to the filing?

UroGen Pharma Ltd. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001437749-25-027874.txt : 20250827 0001437749-25-027874.hdr.sgml : 20250827 20250827163334 ACCESSION NUMBER: 0001437749-25-027874 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250826 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250827 DATE AS OF CHANGE: 20250827 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 251265763 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 8-K 1 urgn20250826_8k.htm FORM 8-K urgn20250826_8k.htm false 0001668243 0001668243 2025-08-26 2025-08-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 26, 2025       UROGEN PHARMA LTD.   (Exact name of registrant as specified in its charter)                     Israel   001-38079   98-1460746 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)         400 Alexander Park Drive , 4th Floor Princeton , New Jersey   08540 (Address of principal executive offices)   (Zip Code)   Registrant ’ s telephone number, including area code: +1 ( 646 ) 768-9780       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:             Title of each class   Trading Symbol(s)   Name of each exchange on which registered Ordinary Shares , par value NIS0.01 per share   URGN   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item   5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   (e)   On August 26, 2025, UroGen Pharma Ltd. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders approve

View on Read The Filing